The biotech company collaborates with international partners as cases of hantavirus emerge aboard the MV Hondius
Category: Health
Moderna Inc. announced on May 8, 2026, that it is actively researching vaccines to combat hantaviruses in light of a deadly outbreak aboard the Dutch-flagged cruise ship MV Hondius. The company, based in Cambridge, Massachusetts, is conducting this research in collaboration with the US Army Medical Research Institute of Infectious Diseases and the Vaccine Innovation Center at Korea University College of Medicine. This initiative began prior to the recent viral transmission incident on the Hondius, which has been linked to multiple cases of the disease.
The World Health Organization (WHO) has reported at least six confirmed cases of hantavirus infection among passengers, with two additional suspected cases. Tragically, three passengers have died during the outbreak. Following the announcement of its vaccine research, Moderna's stock saw a notable increase, rising by approximately 13 percent during midday trading in New York, indicating renewed investor confidence.
Hantavirus, primarily transmitted through rodent droppings, can lead to Hantavirus Pulmonary Syndrome (HPS), a severe respiratory disease with a fatality rate exceeding 30%. The emergence of this outbreak has raised questions about the potential for hantavirus to pose a larger public health threat, even as health experts downplay the risk. Moderna's involvement reflects its broader commitment to developing countermeasures against various infectious diseases.
In recent months, the MV Hondius set sail from Argentina, and the initial reports of hantavirus cases surfaced in April 2026. As of now, the WHO has identified eight cases linked to the cruise, with three confirmed and five suspected cases. One of the deceased was a Dutch woman who left the ship during a stop at St Helena on April 24, later passing away in South Africa two days after disembarking. The other two deaths are still under investigation, with one victim being a German woman whose case is not yet confirmed.
Transmission of hantavirus between humans is rare, and both the WHO and the UK Health Security Agency have stated that the risk to the general public remains low. Nevertheless, the outbreak has prompted health authorities to implement strict isolation protocols aboard the Hondius, where 146 remaining passengers and crew members are currently being monitored.
Moderna’s research into hantavirus vaccines is part of a larger strategy to leverage its mRNA technology, which gained prominence during the COVID-19 pandemic. The company is also working on a late-stage clinical trial for a bird flu vaccine, following the termination of funding from the US Department of Health and Human Services for various vaccine programs last year. Moderna aims to launch 15 new products within five years, which includes its investigational hantavirus vaccine.
Moderna's investigational hantavirus vaccine has shown promising results in early-stage trials. On May 7, 2026, the company reported that its Phase 1 study demonstrated the vaccine was well-tolerated and produced strong immune responses at all dose levels. This is particularly notable as there is currently no FDA-approved hantavirus vaccine available. The encouraging data has led to a 14.38% surge in Moderna's stock, signaling optimism among investors about the company's mRNA pipeline.
As the situation aboard the Hondius continues to develop, health authorities are coordinating the repatriation of passengers and crew. The company’s commitment to vaccine development is bolstered by its ability to respond rapidly to potential pandemics using mRNA technology, which allows for a quicker response than traditional vaccine methods that often require months to grow the virus.
In addition to Moderna's efforts, an international team of scientists, including researchers from the University of Bath and institutions in the US and South Africa, is also developing a vaccine against hantavirus. This team is employing a novel method called ensilication, which aims to create thermally stable vaccines that can be delivered more easily, even via drone. Professor Asel Sartbaeva, a chemist involved in this research, emphasized the potential impact of developing a vaccine to prevent future outbreaks.
As of now, the outbreak aboard the MV Hondius has underscored the importance of continued vigilance and research into infectious diseases. With the WHO monitoring the situation closely and health officials working to control the outbreak, the next steps for both Moderna and the scientific community will be to advance vaccine development and address the health risks posed by hantaviruses. The urgency of these efforts is evident as the global community seeks to mitigate the threats of infectious diseases.